Page last updated: 2024-10-28

ha14-1 and Lymphoma, Large B-Cell, Diffuse

ha14-1 has been researched along with Lymphoma, Large B-Cell, Diffuse in 3 studies

ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate: a BH3 mimetic; synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia

Lymphoma, Large B-Cell, Diffuse: Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Akl, H1
La Rovere, RM1
Janssens, A1
Vandenberghe, P1
Parys, JB1
Bultynck, G1
Dasmahapatra, G1
Lembersky, D1
Rahmani, M1
Kramer, L1
Friedberg, J1
Fisher, RI1
Dent, P1
Grant, S1
Hertan, LM1
Koumenis, C1

Other Studies

3 other studies available for ha14-1 and Lymphoma, Large B-Cell, Diffuse

ArticleYear
HA14-1 potentiates apoptosis in B-cell cancer cells sensitive to a peptide disrupting IP 3 receptor / Bcl-2 complexes.
    The International journal of developmental biology, 2015, Volume: 59, Issue:7-9

    Topics: Apoptosis; B-Lymphocytes; Benzopyrans; Cell Line, Tumor; Endoplasmic Reticulum; Humans; Inositol 1,4

2015
Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress.
    Cancer biology & therapy, 2009, Volume: 8, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzopyrans; Boronic Acids; Bortezomib; Cell Line, T

2009
Piling up the JNK: drug synergy through ER stress.
    Cancer biology & therapy, 2009, Volume: 8, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzopyrans; Boronic Acids; Bortezomib; Drug Synergi

2009